Search results with tag "Ankylosing spondylitis"
New Brunswick Drug Plans Special Authorization Criteria ...
www2.gnb.caAnkylosing Spondylitis For the treatment of patients with active ankylosing spondylitis who are refractory, intolerant or have contraindications to conventional therapy. Claim Notes: • Must be prescribed by a rheumatologist or internist. • Combined use of …
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu(including in patients with psoriatic arthritis and ankylosing spondylitis). Caution should be exercised when considering concomitant use of other immunosuppressants and secukinumab (see also section 4.5). 4.5 Interaction with other medicinal products and other forms of interaction
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euAnkylosing spondylitis 5mg/kg given as an intravenous infusion followed by additional 5mg/kg infusion doses at 2 and 6weeks after the first infusion, then every 6 to 8weeks. If a patient does not respond by 6weeks (i.e. after 2doses), no additional treatment with infliximab should be given. Psoriatic arthritis
New Brunswick Drug Plans Special Authorization Criteria ...
www2.gnb.ca• For the treatment of patients with moderate to severe ankylosing spondylitis (e.g. Bath AS Disease Activity Index (BASDAI) score ≥ 4 on 10 point scale) who: